Profil bibliographique

Gauri Sunkersett

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

9Publications signalées

0Citations signalées

1Affiliations récentes

Institutions déclarées

AbbVie (United States)

Domaines associés

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchLung Cancer Treatments and MutationsCell death mechanisms and regulationMultiple Myeloma Research and Treatments

Publications récentes

Accès ouvert 2026 articleOpenAlex

IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab vs Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma

Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

POSTER: IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND

Kim Linton, Moshe Levy, Dai Maruyama, Abel Costa et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

POSTER: IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma

Lorenzo Falchi, Marcel Nijland, Kim Linton, Neta Goldschmidt et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

ORAL ABSTRACT: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) Versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)

Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

POSTER: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab vs Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma

Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

IBCL-1346: Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 vs Real-World Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma

Habte Yimer, Lorenzo Falchi, Rong Tao, Loic Ysebaert et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND

Kim Linton, Moshe Levy, Dai Maruyama, Abel Costa et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

POSTER: IBCL-1346: Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 vs Real-World Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma

Habte Yimer, Lorenzo Falchi, Rong Tao, Loic Ysebaert et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma

Lorenzo Falchi, Marcel Nijland, Kim Linton, Neta Goldschmidt et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.